Overview

STATEMENT OF NEED

Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are expected to occur in the United States this year, and around 12,830 people are likely to die of the disease (ACS, 2020). Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. Multiple myeloma is primarily considered a disease of older adults, with a median age at diagnosis of 69 years (NCCN, 2020). The incidence is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year relative survival rate remains only 53.9% (NCI, 2020). For the majority of patients who relapse, treatment is complex, and outcomes worsen with each relapse (Siegel et al, 2020).

TARGET AUDIENCE

Hematologist/oncologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with MM.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Distinguish criteria for biochemical vs clinical relapse in MM and indications for therapy
• Assess recent clinical trial findings on novel sequential treatment approaches for relapsed/refractory MM, including maintenance options
• Evaluate strategies to monitor and manage adverse events associated with novel therapies for relapsed/refractory MM 

FACULTY

Shaji Kumar, MD, (Chairperson)
Professor of Hematological Malignancies
Mayo Clinic Cancer Center

Caitlin Costello, MD
Associate Clinical Professor of Medicine
Moores Cancer Center

Sergio Giralt, MD
Chief Attending Physician, Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center

Ajay Nooka, MD, MPH, FACP
Associate Professor of Hematology & Medical Oncology
Emory University School of Medicine

Noopur Raje, MD
Director of the Center for Multiple Myeloma
Massachusetts General Cancer Center

REGISTRATION

There is no fee to participate in or claim CME/NCPD credit for this activity.

Provided by

Jointly Accredited Provider

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:

• Care Continuum
• Oncology Nursing Practice
• Palliative Care
• Symptom Management
• Treatment

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies.

The i3 Health planners, reviewers, and managers have nothing to disclose.

Shaji Kumar, MD, discloses that he has served on an advisory board or panel for AbbVie, Amgen, Antengene, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Janssen, Genentech/Roche, Kite, Oncopeptides, and Takeda, and that he has received grants or research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARSgen, Genentech/Roche, Janssen, Kite, Merck, Novartis, Takeda, and TeneoBio.

Caitlin Costello, MD, discloses that she has served on an advisory board or panel for Bristol Myers Squibb, Janssen, Karyopharm, and Oncopeptides. Dr. Costello has also received grants/research support from Bristol Myers Squibb, Janssen, Poseida, and Takeda.

Sergio Giralt, MD, discloses that he has served as a consultant for Actinuum, Amgen, Celgene, Jazz, Kite, Miltenyi, Novartis, and Omeros. Dr. Giralt has also received grants/research support from Actinuum, Amgen, Celgene, Jazz, Miltenyi, Novartis, Omeros, and Takeda.

Ajay Nooka, MD, MPH, FACP, discloses that he has served on an advisory board or panel for Adaptive Biotech, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi, and Takeda.

Noopur Raje, MD, discloses that she has served as a consultant for Amgen, Bluebird Bio, Bristol Myers Squibb, Caribou Biosciences, Celgene, and Janssen.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by independent educational grants from BMS, Karyopharm, and Sanofi.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it..